Skip to main navigation Skip to search Skip to main content

Very-high-power short-duration ablation for treatment of premature ventricular contractions – The FAST-AND-FURIOUS PVC study

Christian Hendrik Heeger*, Sorin S. Popescu, Bettina Kirstein, Sascha Hatahet, Anna Traub, Huong Lan Phan, Marcel Feher, Gabriele D́Ambrosio, Ahmad Keelani, Michael Schlüter, Julia Vogler, Charlotte Eitel, Karl Heinz Kuck, Roland R. Tilz

*Corresponding author for this work

Abstract

Objectives: We sought to assess the efficacy, safety and short-term clinical outcome of very high-power short-duration (vHP-SD) radiofrequency (RF) catheter ablation for the treatment of idiopathic PVCs originating from the cardiac outflow tract (OT). Background: Power-controlled RF ablation is a widely used technique for the treatment of premature ventricular contractions (PVCs). A novel ablation catheter offers three microelectrodes and six thermocouples at its tip and provides temperature-controlled vHP-SD (90 Watts/4 s,) with the opportunity to switch to moderate-power mode. Methods: In this pilot study, twenty-four consecutive, prospectively enrolled patients underwent PVC ablation utilizing the vHP-SD ablation (study group) and were compared with 24 consecutive patients previously treated with power-controlled ablation (control group). Each group included 12 patients with PVCs originating from the right ventricular OT (RVOT) and 12 patients with PVCs originating from the left ventricular OT (LVOT). The acute endpoint was PVC elimination and was achieved in all patients. Results: In 16/24 (67%) patients (study group) it was achieved by using vHP-SD only. The median RF delivery time was 52 (interquartile range [IQR] 16, 156) seconds (study group) and 350 (IQR 240, 442) seconds (control group, p < 0.0001). No difference was observed regarding procedure duration (p = 0.489) as well as 6-months follow-up (p = 0.712). One (4%, study group) and 2 (8%, control group) severe adverse events occured (p = 0.551). Conclusion: In this study, vHP-SD PVC ablation was similarly effective and safe as compared to conventional power-controlled ablation. The RF time was significantly shorter.

Original languageEnglish
Article number101042
JournalIJC Heart and Vasculature
Volume40
ISSN2352-9067
DOIs
Publication statusPublished - 06.2022

Funding

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CHH received travel grants and research grants from Boston Scientific, Biosense Webster and Cardiofocus and speaker honoraria from Boston Scientific, Biosense Webster and Cardiofocus. CE received travel grants and research grants from Boston Scientific and Biosense Webster and speaker honoraria from Biosense Webster, Medtronic, Boston Scientific and Abbott Medical. RRT is a consultant for Boston Scientific, Biotronik and Biosense Webster and received speaker honoraria from Biosense Webster, Medtronic, Boston Scientific and Abbot Medical. KHK reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster outside the submitted work. All other authors have no relevant disclosures.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Centers: Cardiological Center Luebeck (UHZL)

DFG Research Classification Scheme

  • 2.22-12 Cardiology, Angiology

Fingerprint

Dive into the research topics of 'Very-high-power short-duration ablation for treatment of premature ventricular contractions – The FAST-AND-FURIOUS PVC study'. Together they form a unique fingerprint.

Cite this